Welcome to our dedicated page for Klotho Neurosciences news (Ticker: KLTO), a resource for investors and traders seeking the latest updates and insights on Klotho Neurosciences stock.
Klotho Neurosciences, Inc. (KLTO) is a biopharmaceutical innovator developing therapies for neurodegenerative disorders through its patented s-KL gene technology. This page provides essential updates on clinical trials, research advancements, and strategic developments shaping the company's trajectory in neurological healthcare innovation.
Investors and industry observers will find authoritative coverage of KLTO's progress in gene therapy applications, regulatory milestones, and scientific discoveries. The curated news collection spans clinical-stage program updates, partnership announcements, and peer-reviewed research insights relevant to Alzheimer's, Parkinson's, and ALS therapies.
All content undergoes rigorous verification to ensure accuracy and compliance with financial reporting standards. Users can expect timely updates on therapeutic developments, intellectual property advancements, and expert analysis of KLTO's position within the competitive biopharma landscape.
Bookmark this page for centralized access to verified KLTO developments, with new content added as company announcements and validated industry reports become available.
Klotho Neurosciences (NASDAQ: KLTO), a biotechnology company developing cell and gene therapies for ALS, Alzheimer's, and Parkinson's disease, will present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco. The presentation is scheduled for January 14, 2025, at 3:00 PM PT at the Hilton San Francisco Union Square.
CEO Dr. Joseph Sinkule will discuss the company's work with the secreted form of the Klotho anti-aging gene ('s-KL'), their patent-protected development platform. The company aims to increase awareness of this 'master gene' and its potential role in treating neurodegenerative diseases. They are progressing toward clinical trials for ALS and seeking development partnerships for Alzheimer's and Parkinson's treatments.
KLTO has secured exclusive worldwide licenses from UAB and ICREA in Spain, with patents issued in the USA, Europe, and China for their therapeutic approach using s-KL to treat cognitive and behavioral impairments.
Klotho Neurosciences (NASDAQ: KLTO) has appointed Dr. Merit Cudkowicz to its Scientific Advisory Board. Dr. Cudkowicz is the Chair of Neurology at Massachusetts General Hospital, Director of the Sean M. Healey & AMG Center for ALS, and Julieanne Dorn Professor of Neurology at Harvard Medical School. She is a member of the National Academy of Medicine and co-director of the Northeast ALS Consortium, overseeing 150+ clinical sites in the US and Canada.
The company, focused on developing cell and gene therapies for ALS, Alzheimer's, and Parkinson's disease, aims to leverage Dr. Cudkowicz's expertise in clinical trial design and execution. Their approach centers on a patent-protected product candidate expressing the Klotho gene transcribed protein called 's-KL' or 'secreted Klotho' for ALS treatment.
Klotho Neurosciences (NASDAQ: KLTO) has appointed Riad El-Dada, former US President of Merck, to its Board of Directors. During his tenure at Merck, El-Dada managed over $12 billion in revenue across multiple therapeutic areas and served as Managing Director for Australia and New Zealand operations. His experience includes product development, commercialization, strategic partnerships, and policy engagement through the Healthcare Leadership Council. The appointment aims to strengthen the company's development of S-KL, a patent-protected Klotho gene therapy targeting ALS, Alzheimer's, and Parkinson's diseases.
Klotho Neurosciences (NASDAQ: KLTO) announces the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o is renowned for discovering the Klotho gene, known as the 'anti-aging gene,' during his research at the National Institute of Neuroscience in Tokyo. His research showed that mice lacking the Klotho gene aged faster, while those overexpressing it lived longer. The company is developing a patent-protected secreted form of Klotho (s-KL) for treating neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's disease.
Klotho Neurosciences (NASDAQ: KLTO) has appointed Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its new Chief Operating Officer (COO). This strategic move aims to strengthen the company's leadership team and accelerate the development of its therapeutic candidates. Moriarty brings extensive experience in the pharmaceutical industry, including leadership roles at multinational companies and entrepreneurial success.
Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, highlighted Moriarty's expertise in operational management, strategic execution, and corporate culture development. Moriarty expressed enthusiasm for joining KLTO, citing its robust portfolio and promising cell and gene therapy platform. The company's focus is on developing breakthrough treatments for neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's, leveraging its exclusive worldwide license from the Autonomous University of Barcelona for treatments based on the secreted form of the Klotho gene (s-KL).
Klotho Neurosciences (NASDAQ: KLTO) has announced that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. Dr. Langer, a renowned biotech leader and MIT professor, will contribute his expertise in neuroscience and therapeutics development. Klotho Neurosciences is developing novel therapies for neurodegenerative diseases, leveraging research on the Klotho protein, an anti-aging factor with neuroprotective potential.
The company's platform focuses on the secreted form of Klotho, s-KL, which is patented in several countries. Dr. Joseph Sinkule, Chairman and CEO of Klotho Neurosciences, expressed enthusiasm about Dr. Langer's vast experience in translational medicine and therapeutic innovation. Dr. Langer will provide guidance on the scientific and clinical development of the company's product candidates, supporting efforts to address major unmet medical needs in neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's disease.
